New insulin secretagogues for the treatment of type 2 diabetes

Disease Management and Clinical Outcomes

Volumn 1, Issue 4, 1998, Pages 129-135

  Perfetti, R ^a   Mathur, R ^a   Egan, J M ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,1 DIMETHYL 2 (2 MORPHOLINOPHENYL)GUANIDINE FUMARATE; 2 (N PHENYLINDOYL)IMIDAZOLE; 2 METHOXY 4 [2 [2 (3,5 DIMETHYL 1 PIPERIDINYL)NICOTINAMIDO]ETHYL]BENZOIC ACID; BENZOIC ACID DERIVATIVE; BIGUANIDE DERIVATIVE; GLIMEPIRIDE; GLIQUIDONE; GLUCAGON LIKE PEPTIDE 1; IMIDAZOLINE DERIVATIVE; MEGLITINIDE; METFORMIN; MITIGLINIDE; NATEGLINIDE; NN 623; ORAL ANTIDIABETIC AGENT; PRAMLINTIDE; REPAGLINIDE; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG;

DIABETES CONTROL; DIABETES MELLITUS; DRUG EFFICACY; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; INTRAVENOUS DRUG ADMINISTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL DRUG ADMINISTRATION; PANCREAS ISLET BETA CELL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031765603     PISSN: 10883371     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1088-3371(98)00010-2     Document Type: Review

References (56)

1. G.C. Weir J.L. Leahy Joslin’s diabetes mellitus 1994 Lea & Febiger Malvern, PA
2. J.D. Wilson D.W. Foster Williams’ textbook of endocrinology 1985 W.B. Saunders Company Philadelphia
3. Medical management of non-insulin-dependent (type II) diabetes. Clinical Education Series 3rd Ed. Alexandria, VA. American Diabetes Association Inc.; 1996.
4. American Diabetes Association Clinical Practice Recommendations. Diabetes Care 19(Suppl 1):S1–S117, 1996.
5. W.Y. Fujimoto Overview of non-insulin-dependent diabetes mellitus (NIDDM) in different population groups Diabetic Med 13 Suppl 6 1996 7 10
6. P. Arver T. Pollare H. Lilhell Different etiologies of type 2 (non-insulin-dependent) diabetes mellitus in obese, and non-obese subjects Diabetologia 34 1991 483 487
7. M.M. Byrne J. Sturis R.J. Sobel K.S. Polonsky Elevated plasma glucose 2 h postchallenge predicts defects in beta-cell function Am J Physiol 270 1996 E572 E579
8. A. Vaag J.E. Henriksen S. Madsbad N. Holm H. Beck-Nielsen Insulin secretion, insulin action, and hepatic glucose production in identical twins discordant for non-insulin dependent diabetes mellitus J Clin Investigation 95 1995 690 698
9. D. Moller C. Bjorbek A. Vidal-Puig Candidate genes for insulin resistance Diabetes Care 19 1996 396 400
10. J.H. Karam Reversible insulin resistance in non-insulin dependent diabetes mellitus Hormone Metab Res 28 1996 440 444
11. H. Yki-Jarvinen Role of insulin resistance in the pathogenesis of NIDDM Diabetologia 38 1995 1378 1388
12. S.M. Haffner The insulin resistance syndrome revisited Diabetes Care 19 1996 275 277
13. R.A. De Fronzo R. Hendler D. Simonson Insulin resistance is a prominent feature of insulin-dependent diabetes Diabetes 31 1982 795 801
14. Z.T. Bloomgarden American Diabetes Association Annual Meeting 1996 The etiology of type II diabetes, obesity, and the treatment of type II diabetes Diabetes Care 19 1996 1311 1315
15. R.B. Goldberg S.M. Holvey J. Schneider Dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The glimepiride protocol 201 study group Diabetes Care 19 1996 849 856
16. P. Smits T. Thien Cardiovascular effects of sulphonylurea derivatives. Implications for the treatment of NIDDM? Diabetologia 38 1996 116 121
17. Z.T. Bloomgarden New and traditional treatment of glycemia in NIDDM Diabetes Care 19 1996 295 299
18. R. Rosskamp K. Wernicke-Panten E. Draeger Clinical profile of the novel sulphonylurea glimepiride Diabetes Res Clin Practice 31 Suppl 1996 S33 S42
19. G. Pogatsa What kind of cardiovascular alterations could be influenced positively by oral antidiabetic agents? Diabetes Res Clin Practice 31 Suppl 1996 S27 S31
20. H. Nicolai R. Brickl H. Eschey A. Greischel G. Heinzel E. Konig J. Limmer E. Rupprecht Duration of action and pharmacokinetics of the oral antidiabetic drug gliquidone in patients with non-insulin-dependent (Type 2) diabetes mellitus Arzneimittel-Forschung 47 1997 247 252
21. F. Gregorio F. Ambrosi P. Filipponi S. Cristallini F. Santeusanio Glucose modulates the amount but not the kinetics of insulin release by sulphonylureas J Diabetes & its Complications 8 1994 204 212
22. A.D. Harrower Pharmacokinetics of oral antihyperglycemic agents in patients with renal insufficiency Clin Pharmacokinetics 31 1996 111 119
23. W.J. Malaisse Stimulation of insulin release by non-sulfonylurea hypoglycemic agents the meglitinide family Hormone & Metabolic Res 27 1995 263 266
24. B.H.R. Wolffenbuttel M.B. Graal New treatments for patients with type 2 diabetes mellitus Postgrad Med J 72 1996 657 662
25. A. Bakkali Nadi T.M. Zhang W.J. Malaisse Effects of the methyl esters of pyruvate, succinate and glutamate on the secretory response tomeglitinide analogues in rat pancreatic islets Pharmacol Res 33 1996 191 194
26. C. Vinambres M.L. Villaneva-Penarillo I. Valverde W.J. Malaisse Repaglinide preserves nutrient-stimulated biosynthetic activity in rat pancreatic islets Pharmacological Res 34 1996 83 85
27. E. Nakashima J. Nakamura N. Koh F. Sakakibara Y. Hamada N. Hotta Effect of a novel hypoglycemic agent, KAD-1229 on glucose metabolism and fructose-2,6-bisphosphate content in isolated hepatocytes of normal rats Diabetes Res Clin Practice 34 1996 13 22
28. H. Ohnota T. Koizumi N. Tsutsumi M. Kobayashi S. Inoue F. Sato Novel rapid- and short-acting hypoglycemic agent, a calcium (2s)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl) propionate (KAD-1229) that acts on the sulfonylurea receptor comparison of effects between KAD-1229 and gliclazide J Pharmacol Exp Ther 269 1994 489 495
29. A.M. Rabuazzo M. Buscema C. Vicini V. Caltabiano M. Vetri F. Forte R. Vigneri F. Purrello Glyburide and tolbutamide induce desensitization of insulin release in rat pancreatic islets by different mechanisms Endocrinology 131 1992 1815 1820
30. A.M. Davalli A.E. Pontiroli G. Socci F. Bertuzzi B. Fattori S. Braghi V.D. Carlo G. Pozza Human islets chronically exposed in vitro to different stimuli become unresponsive to the same stimuli given acutely evidence supporting specific desensitization rather than beta-cell exhaustion J Clin Endocrinol Metab 74 1992 790 794
31. C.A. Skillman P. Raskin A double-masked placebo-controlled trial assessing effects of various doses of BTS 67 582, a novel insulinotropic agent, on fasting hyperglycemia in NIDDM patients Diabetes Care 20 1997 591 596
32. M.J. Dunne C. Kane E.A. Harding J.H. Jaggar R.B. Jones S.J.H. Ashcroft BTS 67582 a novel insulin releasing agent Diab Med 12 Suppl 1 1995 S31 S32 (Abstract)
33. T. Ikenoue K. Okazaki S. Fujitani Y. Tsuchiya M. Akiyoshi T. Maki N. Kondo Effect of a new hypoglycemic agent, A4166 [(−)- N (trans-4isoprylcyclohexanecarbonyl)- d -phenylalanine], on postprandial blood glucose excursion comparison with voglibose and glibenclimide Biol Pharm Bull 20 1997 354 359
34. M. Akiyoshi M. Kakei M. Nakazaki H. Tanaka A new hypoglycemic agent, A-4166, inhibits ATP-sensitive potassium channels in rat pancreatic beta-cells Am J Physiol 268 1995 E185 E193
35. Kikuki M. Modulation of insulin secretion in non-insulin dependent diabetes mellitus by two novel oral hypoglycemic agents, NN623 and A4166. Diabetes Med 13(9 Suppl 6):S:151–155, 1996
36. S.V. Zaitsev A.M. Efanov I.B. Efanova O. Larsson C.G. Ostenson G. Gold P.O. Berggren S. Efendic Imidazoline compounds stimulate insulin release by inhibition of K-ATP channels and interaction with exocytotic machinery Diabetes 45 1996 1610 1618
37. 2+ mobilization from thapsigargin-sensitive stores in mouse pancreatic β cells Diabetes 47 1998 211 218
38. M.A. Nauck M.M. Heimesaat C. Orskov J.J. Holst R. Ebert W. Creutzfeldt Preserved incretin activity of glucagon-like peptide-1 [7-36 amide] but not human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus J Clin Invest 91 1993 301 307
39. G.J. Cooper C.A. Tse Amylin, amyloid and age related disease Drugs Aging 9 1996 202 212
40. G.I. Bell R.F. Santerre G.T. Mullenhach Hamster preproglucagon contains the sequence of glucagon and related peptides Nature (London) 302 1983 716 718
41. J.J. Holst Glucagon-like peptide-1 (GLP-1) a newly discovered GI hormone Gastroenterology 107 1994 1048 1055
42. C. Orsakov Glucagon-like peptide-1, a new hormone of the enteroinsular axis Diabetologia 35 1992 701 711
43. M.A. Nauck R. Stockman R. Ebert W. Creutzfeldt Reduced incretin effects in type 2 (non-insulin dependent) diabetes Diabetologia 29 1986 46 52
44. M.A. Nauck N. Kleine C. Orskov J.J. Holst B. Willms W. Creutzfeldt Normalization of fasting hyperglycemia by exogenous glucagon-like peptide-1 [7-36 amide] in type 2 (non-insulin dependent) diabetic patients Diabetologia 36 1993 741 744
45. Y. Tanizawa A.C. Riggs S.C. Elbein A. Whelan H. Donis-Keller M.A. Permutt Human glucagon-like peptide-1 receptor gene in NIDDM identification and use of simple sequence repeat polymorphism in genetic analysis Diabetes 43 1994 752 757
46. Y. Zhang I.T.E. Cook A.T. Hattersley R. Firth P.I. Saker M. Warren-Perry M. Stoffel R.C. Turner Non-linkage of the glucagon-like peptide-1 receptor gene with maturity onset diabetes of the young Diabetologia 37 1994 721 724
47. M. Gutniak C. Orskov J.J. Holst B. Ahren S. Efandic Antidiabetic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and in patients with diabetes mellitus N Engl J Med 326 1992 1316 1322
48. W.O. Creutzfeldt N. Kleine B. Willms C. Orskov J.J. Holst M.A. Nauck Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide (7-36) amide in type 1 diabetes Diabetes Care 19 1996 580 586
49. A. Wettergren B. Schjoldager P.E. Mortesen J. Myhre J. Christiansen J.J. Holst Truncated GLP-1 (proglucagon 78-107 amide) inhibits gastric and pancreatic function in man Dig Dis Sci 38 1993 665 673
50. J. Schirra U. Wank P. Houck B. Goke M. Katcschinski Effects of GLP-1 on human antro-pyloroduodenal motility Gastroenterology 110 1996 A1116
51. B. Willms J. Werner P. Holst C. Orskov W. Creutzfeldt M.A. Nauch Gastric emptying, glucose responses, and insulin secretion after a liquid meal effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (non-insulin-dependent) diabetic patients J Clin Endocrinol Metab 81 1996 327 332
52. J. Dupre M.T. Behne I.M. Hramiak P. McFurlane P. Williamson P. Zabel T.J. Mc Donald Glucagon-like peptide-1 reduces postprandial glycemic excursion in IDDM Diabetes 44 1995 626 630
53. R. Ritzel C. Orskov J.J. Holst M. Nauck Pharmacokinetic, insulinotropic glucagonostatic properties of GLP-1 after subcutaneous injection in healthy volunteers. Dose-response relationships Diabetologia 38 1995 720 725
54. J. Rauchman B.A. Barrow J.C. Levy R.C. Turner Near normalization of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM Diabetologia 40 1997 205 211
55. C. Moyses A. Young O. Kolterman Modulation of gastric emptying as a therapeutic approach to glycemic control Diabetic Medicine 13 1996 S34 S38
56. O.G. Koltermann A. Gottlieb C. Moyses W. Colbum Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC137, a human amylin analogue Diabetes Care 18 1995 1179 1182